Dryad
Published March 23, 2016 | Version v1
Dataset Open

Data from: Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis

Creators

  • 1. University of Edinburgh
  • 2. University of Leeds
  • 3. National Hospital for Neurology and Neurosurgery

Description

Objective: To develop and implement an evidence based framework to select, from drugs already licenced, candidate oral neuroprotective drugs to be tested in secondary progressive multiple sclerosis. Design: Systematic review of clinical studies of oral putative neuroprotective therapies in MS and four other neurodegenerative diseases with shared pathological features, followed by systematic review and meta-analyses of the in vivo experimental data for those interventions. We presented summary data to an international multi-disciplinary committee, which assessed each drug in turn using pre-specified criteria including consideration of mechanism of action. Results: We identified a short list of fifty-two candidate interventions. After review of all clinical and pre-clinical evidence we identified ibudilast, riluzole, amiloride, pirfenidone, fluoxetine, oxcarbazepine, and the polyunsaturated fatty-acid class (Linoleic Acid, Lipoic acid; Omega-3 fatty acid, Max EPA oil) as lead candidates for clinical evaluation. Conclusions: We demonstrate a standardised and systematic approach to candidate identification for drug rescue and repurposing trials that can be applied widely to neurodegenerative disorders.

Notes

MS PLoS dataset
Excel file extract from MS Access database describing clinical studies indentified in the review, and our assessment of their risk of bias

Files

Files (226.5 kB)

Name Size Download all
md5:8d8c3e51b39f4811de02fc9fb512fce1
226.5 kB Download

Additional details

Related works

Is cited by
10.1371/journal.pone.0117705 (DOI)